Inmune Bio, Inc.

INmune Bio develops two late-stage immunotherapy platforms: CORDStrom, allogeneic mesenchymal stromal cells for rare skin disease, advancing toward regulatory filings; and XPro1595, a TNF-targeting therapy for neuroinflammation with FDA Fast Track designation.